Who is sponsoring NCT07363538?

NCT07363538 is sponsored by Central China Fuwai Hospital of Zhengzhou University.

What drugs are being tested in NCT07363538?

Interventions in NCT07363538: Surgical operation is performed on neonates aged >7 days (postnatal age), Surgical operation is performed on neonates aged < 7 days (postnatal age)..

What condition does NCT07363538 study?

NCT07363538 studies Complex Congenital Heart Disease.

Is NCT07363538 still recruiting?

NCT07363538 is currently recruiting now. Last updated 23 January 2026.

Last reviewed 2026-01-23 · How we verify

NCT07363538

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multicenter Randomized Controlled Trial (RCT) and Efficacy Evaluation System Study on Surgical Innovation Strategies for Neonatal Complex Congenital Heart Disease

Recruiting now NA Last updated 23 January 2026

What this trial tests

NA trial testing Surgical operation is performed on neonates aged >7 days (postnatal age) in Complex Congenital Heart Disease in 738 participants. Currently enrolling.

Timeline

1 December 2025

Primary endpoint
31 January 2029

31 January 2029

Quick facts

Lead sponsor	Central China Fuwai Hospital of Zhengzhou University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	738
Start date	1 December 2025
Primary completion	31 January 2029
Estimated completion	31 January 2029
Sites	12 locations across China

Drugs / interventions tested

Surgical operation is performed on neonates aged >7 days (postnatal age)
Surgical operation is performed on neonates aged < 7 days (postnatal age).

Conditions studied

Complex Congenital Heart Disease — all drugs for Complex Congenital Heart Disease →

Sponsor

Central China Fuwai Hospital of Zhengzhou University

Who can join

Under 7 Days, any sex, with Complex Congenital Heart Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There remains controversy regarding the optimal timing of surgical treatment for neonatal CCHD (Complex Congenital Heart Disease). Based on the established national multi-center database for surgical treatment of congenital heart disease and the prenatal-postnatal integrated diagnosis and treatment model, this study will conduct a multi-center RCT (Randomized Controlled Trial) to explore the optimal surgical timing for neonatal CCHD. It will also develop innovative comprehensive treatment strategies for critically ill neonatal CCHD patients, use RCT data to evaluate treatment efficacy and establish an evaluation system. This system will be gradually promoted nationwide, aiming to reduce the incidence of perioperative mortality and non-recovery discharge in CCHD patients by 50% (National in-hospital mortality rate of neonatal congenital heart disease surgery in 2023: 6.5%; non-recovery discharge rate: 12.66%), thereby improving the overall level of CCHD treatment in China.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Complex Congenital Heart Disease

Currently open trials in the same condition.

NCT06884046 — Support for the Management of Parental Stress in Surgical Resuscitation of Congenital Heart Diseases · NA · recruiting
NCT07524998 — A Chinese Multicenter Study on Surgical Techniques and Outcomes Across the Lifespan in Congenital Heart Disease · recruiting

Other Central China Fuwai Hospital of Zhengzhou University trials

Trials by the same sponsor.

NCT07113769 — Plasma Biomarkers and Platelet Morphology of Extracorporeal CardioPulmonary Resuscitation · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07363538 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Central China Fuwai Hospital of Zhengzhou University
Last refreshed: 23 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07363538.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing